HOOKIPA Pharma announces it will not pursue a planned all-share acquisition of Poolbeg Pharma.
Quiver AI Summary
HOOKIPA Pharma Inc. announced that it will not proceed with a planned all-share acquisition of Poolbeg Pharma plc, as discussed in previous communications. This decision follows non-binding discussions and an extension on the potential offer update, indicating that the HOOKIPA Board does not intend to make a formal offer under relevant takeover regulations. However, HOOKIPA retains the option to revisit this decision under specific circumstances outlined in the takeover code. The announcement is regulated as inside information, and it clarifies that no offer or solicitation for securities is currently being made.
Potential Positives
- HOOKIPA Pharma Inc. is actively engaging in potential corporate activity, indicating strategic growth initiatives.
- The company has clarified its position regarding the acquisition talks with Poolbeg Pharma plc, providing transparency to stakeholders.
- By adhering to takeover regulations, HOOKIPA demonstrates compliance and governance, which can bolster investor confidence.
Potential Negatives
- The announcement reveals that HOOKIPA Pharma Inc. has decided not to pursue their interest in acquiring Poolbeg Pharma plc, indicating a potential setback in their strategic growth plans.
- This declaration may create uncertainty around HOOKIPA's market position and its capability to execute significant mergers or acquisitions.
- The announcement falls under inside information regulations, which could lead to scrutiny regarding the company's future intentions and business strategy amidst investor concerns.
FAQ
What is the main announcement from HOOKIPA Pharma?
HOOKIPA Pharma has decided not to make an offer for Poolbeg Pharma following earlier discussions regarding a potential acquisition.
What does Rule 2.8 of the City Code on Takeovers and Mergers entail?
Rule 2.8 restricts parties from making further announcements for a period unless certain conditions are met, such as obtaining Poolbeg's board agreement.
Why is this announcement considered inside information?
The announcement is classified as inside information under the Market Abuse Regulation due to its potential impact on share prices.
How can those in restricted jurisdictions access this announcement?
This announcement will be made available on HOOKIPA's website, subject to restrictions applicable to certain jurisdictions.
Who should inquiries about the announcement be directed to?
Inquiries can be directed to Malte Peters, CEO of HOOKIPA, via the provided contact information in the announcement.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HOOK Hedge Fund Activity
We have seen 0 institutional investors add shares of $HOOK stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KNOLL CAPITAL MANAGEMENT, LLC removed 53,113 shares (-9.6%) from their portfolio in Q4 2024, for an estimated $106,757
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) --
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”).
THIS ANNOUNCEMENT CONSTITUTES INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014, AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.
For immediate release
20 February 2025
HOOKIPA Pharma Inc. (“HOOKIPA”)
Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
Further to the announcement on 2 January 2025 regarding the non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg and the announcement on 30 January 2025 regarding the PUSU extension, the HOOKIPA Board has determined that it does not intend to make an offer for Poolbeg under Rule 2.7 of the Code.
This announcement is made in accordance with Rule 2.8 of the Code.
Under Note 2 on Rule 2.8 of the Code, HOOKIPA and any person(s) acting in concert with it reserve the right to set aside the restrictions in Rule 2.8 of the Code in the following circumstances:
a) with the agreement of the board of Poolbeg;
b) following the announcement of a firm intention to make an offer for Poolbeg, by or on behalf of a third party;
c) following the announcement by Poolbeg of a Rule 9 waiver (as described in Note 1 on the Notes on Dispensations from Rule 9 of the Code) or a reverse takeover (as defined in the Code); or
d) where the Panel on Takeovers and Mergers has determined that there has been a material change of circumstances.
The person responsible for arranging the release of this announcement on behalf of HOOKIPA is Malte Peters, Chief Executive Officer of HOOKIPA.
Enquiries:
|
|
HOOKIPA Pharma Inc. | +43 1 890 63 60 |
Malte Peters, CEO | [email protected] |
Terry Coelho, EVP & CFO | [email protected] |
Moelis & Company | +44 (0) 207 634 3500 |
(Financial Adviser to HOOKIPA)
|
|
London
Chris Raff Simon Chaudhuri |
|
New York
Ashish Contractor |
Important information
This announcement is not intended to, and does not, constitute or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction, whether pursuant to this announcement or otherwise.
The release, distribution or publication of this announcement in jurisdictions outside the United Kingdom may be restricted by laws of the relevant jurisdictions and therefore persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdiction.
Disclaimer
Moelis & Company LLC (“ Moelis ”) is acting as financial adviser to HOOKIPA in connection with the matters set out in this announcement and for no one else and will not be responsible to anyone other than HOOKIPA for providing the protections afforded to its clients nor for providing advice in relation to the matters set out in this announcement. Neither Moelis nor any of its subsidiaries, branches or affiliates and their respective directors, officers, employees or agents owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Moelis in connection with this announcement, any statement contained herein or otherwise
Publication on Website
A copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on HOOKIPA’s website - https://ir.hookipapharma.com/potential-combination# by no later than 12 noon (London time) on the business day following the release of this announcement in accordance with Rule 26.1 of the Code. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.
This announcement is not intended to, and does not, constitute, represent or form part of any offer, invitation or solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities or the solicitation of any vote or approval in any jurisdiction whether pursuant to this announcement or otherwise.